Taken together, the dual capacity of SYK and BTK inhibitors to suppress immune-mediated platelet clearance and diminish autoantibody production underlies their clinical efficacy in improving platelet response in ITP.7 The gene discussed is SYK; the disease is autoimmune thrombocytopenic purpura.